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The margin index was 21% in 2009 and 20% in 2010. Since all drugs were Rx 
(margin was set up to 12%, VAT was fixed to 8%), this was completely expected. At 
the end of 2010, two medicines: levonorgestrel (1,5mg) and orlistat (60mg), were 
authorised as OTC medicines (free pricing, margin:25%, VAT:18%). ConClusions: 
“Lifestyle-medicines” are difficult to define. Market success depends on prod-
uct characteristics, effectiveness, tolerability, convenient drug-delivery format, 
simple dosing regimen, good safety profile, first-to-market position, premium 
prices, sustained media attention, Rx-OTC switch potential and reimbursement 
potential. Although more new “lifestyle-medicines” will be authorised in Serbia, 
market share is expected to decrease because of low purchasing power and low 
reimbursement potential.
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objeCtives: Different external price referencing (EPR) configurations are applied 
by countries worldwide. Depending on how EPR schemes are implemented, 
they may have varying effects on short- and long-run prices, market dynam-
ics, key stakeholders, and other relevant endpoints. This research evaluated 
the merits and demerits of EPR from an efficiency, equity, and quality perspec-
tive. Methods: A theoretical and empirical analysis of the effectiveness of 
EPR was conducted, based on a systematic review of the literature and stake-
holder interviews. As EPR has been most common in Europe, the study focused 
on this region. Results: The systematic review identified 100 relevant articles. 
The articles were categorised according to study characteristics and four major 
themes were identified; these findings were confirmed by the interviewees. The 
evidence suggests that EPR schemes often generate disproportionate price lev-
els in relation to national abilities to pay; this is likely due to the reliance on 
foreign list prices which do not reflect negotiated discounts. If manufacturers 
apply launch strategies to exert upward pressure on prices (e.g. launch delays or 
product withdrawals), it may also limit patient access to life-saving medicines. 
In addition, the bureaucratic complexity of many EPR schemes may undermine 
the objectives of EPR use (i.e. cost containment and macroeconomic efficiency). 
Finally, widespread EPR application may stifle pharmaceutical and biomedical 
innovation. ConClusions: A national pricing policy should provide an effec-
tive, predictable, transparent, and stable pricing environment for pharmaceutical 
products. It should internalise national priorities for health and industrial policy, 
including cost containment, employment, innovation, and trade promotion. EPR 
is associated with important short- and long-term issues. If EPR is going to con-
tinue to be applied by EU Member States and other countries, then it is necessary 
to establish guiding principles to govern EPR use across jurisdictions. Still, dif-
ferential pricing and risk-sharing agreements may represent more sustainable 
policy options.
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objeCtives: Reformulating existing drugs can improve patient convenience, com-
pliance and create new uses for the product. However, reformulations cost millions 
of Euros - a risky investment without guaranteed exclusivity or returns. This study 
assessed whether markets reward incremental value creation through reformu-
lation by comparing sales performance close to patent expiry for reformulated 
and non-reformulated products. Methods: IMS MIDAS data was interrogated to 
identify 829 small molecule, non-generic products which had peak sales above € 5M 
and lost patent protection between 2001 and 2010 in EU-5 (France, Germany, Italy, 
Spain and UK). Ex-manufacturer sales value (€ ) 2 years after patent expiry was 
compared with sales value 4 years earlier to calculate percentage value erosion 
for each of the 829 products. A subset of 133 products which launched at least 1 
reformulation close to patent protection expiry (launch between 3 years before 
and 1 year after patent protection expiry) were analysed to assess whether value 
erosion varied across countries or therapy areas. Results: Mean ex-manufacturer 
sales value erosion of reformulated products (24%) was significantly less than 
non-reformulated products (37%, P< 0.01). Reformulated product value erosion 
varied with country and therapy area. Germany saw highest number of reformu-
lations launched yet only reformulations launched in Italy showed significantly 
less value erosion than non-reformulated products (P< 0.01). Across therapy areas, 
reformulations were most common in nervous system, metabolism and anti-
infective categories. However, reformulated anti-infective product value erosion 
was pronounced while musculoskeletal and nervous system products experi-
enced significantly less value erosion than for non-reformulated products (both 
P< 0.05). ConClusions: Overall, reformulated products do maintain more value 
than non-reformulated products following loss of patent protection. Chronic 
disorders e.g. nervous and musculoskeletal system disorders appear to be the 
most promising areas for reformulating. Future reformulation potential is tightly 
linked to country-specific pricing and market access policy decisions to recognise 
incremental value products.
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objeCtives: To construct a number of pharmaceutical price indices for a broad set 
of countries, covering a range of regions, including countries with different levels 
objeCtives: Competition within therapeutic drug classes from “follow-on” drugs 
has been a highly controversial issue. Manufacturers launching new molecules 
in existing drug classes have often been criticized for inflating health systems’ 
expenses, but it has been argued that such drugs increase therapeutic options. 
Economic theory suggests that follow-on drugs induce price competition. We con-
tribute to this discussion by addressing the topic of pricing at market entry and 
price development in the German market with the distinct focus on competition 
within already existing drug classes. Methods: We measure determinants of 
price strategies of follow-on drugs using regression analyses, considering all new 
molecules launched in the German market in the period from 1993-2008. Prices of 
products are standardized on Defined Daily Dosages controlling for sales volumes 
based on data from the IMS Health DPM database, a census audit of pharmaceutical 
sales in Germany, and for the therapeutic quality of a new product using ratings 
by Fricke/Klaus as a proxy for innovation. Results: We identify prices correlating 
with therapeutic value at market entry. While the first two molecules engage in 
quality competition by offering more therapeutic options, price discounts below the 
market price can be observed from the third entrant on. Price discounts are even 
more distinct in development races with several drugs entering the market within 
two years and in classes with a low degree of therapeutic differentiation. Prices 
remain relatively constant over time. ConClusions: This study contributes to 
assessments of competition in pharmaceutical markets focusing on price strategies 
of new market entrants. After an initial phase of market building, further follow-on 
products induce price competition. Largely unchanged prices after 4 years may be 
interpreted as quality competition and can be attributed to prices in Germany being 
anchor point for international price referencing.
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objeCtives: Although generic drugs are considered to be therapeutically equivalent 
to their off-patent (branded) counterparts, the overall impact of generic substitu-
tion on clinical and economic outcomes has not been comprehensively evaluated. 
The goal of this study was to test whether 1) generics and branded products yield 
the same health outcomes; and 2) generic therapies save economic resources ver-
sus branded therapies for de-novo patients and patients on maintenance ther-
apy. Methods: We performed a systematic literature review in Medline, Cochrane 
Database of Systematic Reviews and Embase (2000-2012) to identify original research 
studies on clinical or economic outcomes with either independent or pre-post com-
parator groups. Data were aggregated using a standardized extraction form. For 
each included study, outcomes were categorized as favoring or opposing generic 
drug substitution. As we compared different outcomes, one publication could 
contribute to multiple outcome comparisons. Results: We included 40 studies 
that led to 121 outcome comparisons. Similar clinical effects were found in 74% 
of all studies in which patients were initiating therapy (de novo) and 64% of all 
studies involving maintenance therapy comparisons. 100% of the economic analy-
ses of de novo patients and 56% of comparisons of maintenance therapy patients 
showed lower costs associated with the use of original brand. Overall, 66% of the 
outcome comparisons reported similar clinical outcomes and 64% suggested that 
brand products lower costs compared to generic substitution. ConClusions: Our 
analyses suggested that clinical effects were mainly similar, whereas economic 
savings of brand to generic drug substitution may be overstated, particularly in 
sensitive therapeutic areas such as anti-epileptic drugs or immunosuppressives. 
More systematic research comparing clinical and cost outcomes with or without 
generic substitution is needed to inform policy on the use of generic substitu-
tion. ACKnoWledGeMents: We would like to thank Anke-Peggy Holtorf and 
Zoltán Kaló for their scientific input.
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objeCtives: To determine whether there was a difference between wholesale 
prices, utilization and market share, as well as to explain Rx-OTC switches and 
reimbursement possibilities of “lifestyle-medicines”, in 2009 and 2010, before and 
after the adoption of new Medicines Law, in Serbia. Methods: We investigated 
how many potential “lifestyle-medicines”, satisfying the previously determined 
criteria, were authorised for sale. Utilization, price changes and reimbursement 
status were monitored. Price index and margin index were calculated using the 
formula: I= QxP (index(I),quantity(Q),price(P)). To compare the differences in prices 
and utilization, non-parametric Mann-Whitney test was used. To test difference 
in market shares, T-test of proportion was used. Results: There were 21 regis-
tered “lifestyle-medicines”. Five medicines (oral contraceptives) were listed. In 
2009, there were 1,763,030 units dispensed worth 16,074,922€ . In 2010, 1,814,405 
units were dispensed while total value was 14,129,792€ . The average sales(€ ) were 
higher in 2009, which is not in line with the expected growth trend, but observed 
difference was not statistically significant. The wholesale price-index 2009/2010 
was -13%. This means that prices were 13% lower in 2010. In fact, during 2010, 
prices remained the same in national currency, which weakened against euro. 
